



June 16, 2025

To whom it may concern

Company Name	Y.A.C. HOLDINGS CO., LTD.
Representative	MOMOSE Takefumi Representative Director, Chairman and President (Code number TSE 6298, TSE Prime)
Inquiries	HATAKEYAMA Osamu Director & General Manager, Administration Headquarter (Tel: +81-42-546-1161)

### **Notice of New Capital Alliance with LINUS BIOTECHNOLOGY, INC. (U.S.A.)**

We (hereafter referred to as “the Company”) hereby announce that our Board of Directors has resolved at a meeting on June 16, 2025 to enter into a new capital alliance agreement with LINUS BIOTECHNOLOGY, INC. (hereafter “Linus Bio”) of the United States as below.

#### **1. Background and Purpose of Capital Alliance**

- (1) As announced in the “Announcement on Business Alliance with LINUS BIOTECHNOLOGY, INC. (U.S.A.)” dated December 9, 2022, our company and Linus Bio have entered into a business alliance agreement for the “Development of equipment to automate the preparatory work for hair exposome analysis and biomarker development” for the “Precision exposome medical companies” of Linus Bio. The two companies concluded a business alliance agreement for the “development of equipment to automate the preparatory work for human hair sectioning and biochemical analysis,” and developed a mounter (heavy metal analysis machine) and a slicer (organic material analysis machine), commonly called SAMURAI, which are used in the analysis scheme at Linus Bio.
- (2) As disclosed in the “Notice Regarding Capital Alliance with LINUS BIOTECHNOLOGY, INC. (U.S.A.)” dated May 11, 2023, for the purpose of strengthening the relationship between the two companies, the Company subscribed to 1 billion yen worth of preferred shares issued by Linus Bio, and in conjunction with this, MOMOSE Takefumi, Chairman and President of the Company, has been appointed as “Senior Technical Advisor” to Linus Bio.
- (3) As disclosed in the “Notice of New Capital Alliance with LINUS BIOTECHNOLOGY, INC. (U.S.A.)” dated July 29, 2024, YAC BIO, Inc. (hereinafter referred to as “YAC BIO”), a 100% subsidiary of the Company, will develop a new equipment that will contribute to the advancement and efficiency of hair analysis level on the part of Linus Bio side, and promote the autism diagnosis business using Linus Bio’s hair analysis. With the aim of further strengthening and accelerating the relationship between the two companies into the future, we subscribed to the US\$5 million worth of preferred equity issued by Linus Bio.
- (4) The purpose of an additional capital alliance is to further enhance the Company’s presence in Linus Bio and to be more involved in the promotion and expansion of Linus Bio’s autism diagnosis business using hair analysis, thereby accelerating the business development and deepening the relationship between the two companies in the future.

#### **2. Details of the new Capital Alliance**

The new capital alliance will include the following.

- (1) We will subscribe for preferred shares (equivalent to US\$ 3 million) to be issued by Linus Bio. The terms and conditions of the issuance and subscription, as well as the timing of the investment, will be finalized in

the future.

- (2) Following the Investment, Linus Bio will appoint one of the Company's officers or employees as a Director. This makes it possible for the Company to be directly involved in the management of Linus Bio.
- (3) When Linus Bio's autism diagnosis business using hair analysis is expanded in the Asian region in the future, we will be able to obtain exclusive rights to operate in the Asian region.

### 3. Outline of Business Alliance Partner

(1) Name	Linus Biotechnology, Inc. (URL : <a href="https://linusbio.com/">https://linusbio.com/</a> )	
(2) Address	675 US Highway 1, North Brunswick, NJ 08902, USA	
(3) Name of representative & Title	Dr. Manish Arora, CEO	
(4) Business content	<p>Linus Bio is a patient-centric, precision exposome medicine company headquartered in North Brunswick, NJ.</p> <p>Originating from the world's leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing.</p>	
(5) Paid up Capital	USD 31,901,503.00 (As of December 31, 2024)	
(6) Date of Establishment	March 31, 2021	
(7) Major shareholders	<p>Dr. Manish Arora</p> <p>Icahn School of Medicine at Mt. Sinai</p> <p>Y.A.C. Holdings Co., Ltd.</p> <p>Bow Capital Fund II, LP</p> <p>Great Point Ventures Innovation Fund III, LP</p>	
(8) Relationship between the target and us	Capital ties	<p>In May 2023, we subscribed to the preferred equity of the company worth 1 billion yen and in July 2024, 5 million US dollars.</p> <p>This time, an additional 3 million US dollars of preferred equity securities issued by Linus Bio will be underwritten.</p>
	Personal relationship	<p>MOMOSE Takefumi, Chairman and President of the Company, has been appointed as "Senior Technical Advisor" to Linus Bio, and allowed to attend the board of directors meetings of Linus Bio as an observer.</p> <p>With this additional investment, he will be able to be directly involved in the management of Linus Bio as a director.</p>
	Business relationship	(See 1 (1) above.)
	Present relationship between the target	Nil

Main customers : Novozymes A/S (Kingdom of Denmark), and other confidential pharmaceutical companies

### 4. Schedule

Date of signing the investment agreement is scheduled for late July 2025 (Japanese Standard Time)

### 5. Future Outlook

Although the impact of this matter on the Company's consolidated results for the fiscal year ending

March 31, 2026 will be minor, we believe that it will contribute to the improvement of the Group's business results in the future. In addition, depending on the progress of the capital and business alliance, we will disclose information in a timely manner if it is judged to be beneficial to shareholders and investors.

End